Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GMNN | O75496 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | SHBG | P04278 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1900865 | 1.00 | EPHX1 (0.48) | EPHX1TP53KDM4EGMNNLMNA | |
| SCHEMBL646456 | 1.00 | EPHX1 (0.48) | EPHX1TP53KDM4EGMNNLMNA | |
| SCHEMBL29257688 | 1.00 | EPHX1 (0.48) | EPHX1TP53KDM4EGMNNLMNA | |
| SCHEMBL2067136 | 1.00 | EPHX1 (0.48) | EPHX1TP53KDM4EGMNNLMNA | |
| SCHEMBL3293988 | 1.00 | EPHX1 (0.48) | EPHX1TP53KDM4EGMNNLMNA | |
| SCHEMBL13416816 | 0.82 | EPHX1 (0.40) | EPHX1TP53KDM4EGMNNLMNA | |
| SCHEMBL16316581 | 0.82 | EPHX1 (0.40) | EPHX1TP53KDM4EGMNNLMNA | |
| SCHEMBL5509761 | 0.82 | EPHX1 (0.40) | EPHX1TP53KDM4EGMNNLMNA | |
| SCHEMBL19538503 | 0.82 | TP53 (0.48) | EPHX1TP53KDM4EGMNNLMNA | |
| SCHEMBL14299180 | 0.82 | EPHX1 (0.40) | EPHX1TP53KDM4EGMNNLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118239988-A | Preparation method and application of heterochiral binuclear Ir (III) metal-organic double-helix structure compound | 大连理工大学 | 2024-06-25 | — | — | CN | claimed |
| CN-114437136-B | Preparation method and application of thiourea functionalized multi-chiral binuclear Ir (III) metal-organic double helix structure | 大连理工大学 | 2023-06-27 | — | — | CN | claimed |
| CN-119119087-A | Chiral binuclear copper complex with benzo [ c ] cinnoline skeleton and preparation method thereof | 中国科学院上海有机化学研究所 | 2024-12-13 | — | — | CN | disclosed |
| CN-118239988-A | Preparation method and application of heterochiral binuclear Ir (III) metal-organic double-helix structure compound | 大连理工大学 | 2024-06-25 | — | — | CN | disclosed |
| US-9108918-B2 | Process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one via a novel intermediate | ALMIRALL, S.A. (ES) | 2015-08-18 | — | — | US | disclosed |
| US-9108918-B2 | Process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one via a novel intermediate | ALMIRALL, S.A. (ES) | 2015-08-18 | — | — | US | disclosed |
| US-20150011769-A1 | PROCESS FOR PREPARING 5-(2--1(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE VIA A NOVEL INTERMEDIATE | ALMIRALL, S.A. (ES) | 2015-01-08 | — | — | US | disclosed |
| US-20150011769-A1 | PROCESS FOR PREPARING 5-(2--1(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE VIA A NOVEL INTERMEDIATE | ALMIRALL, S.A. (ES) | 2015-01-08 | — | — | US | disclosed |
| WO-2013050375-A1 | PROCESS FOR PREPARING 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO}-1(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE VIA A NOVEL INTERMEDIATE | ALMIRALL, S.A. (ES) | 2013-04-11 | — | — | WO | disclosed |
| EP-1661903-B1 | NOVEL TRANSITION METAL COMPLEX AND PROCESS FOR PRODUCING OPTICALLY ACTIVE ALCOHOL WITH THE COMPLEX | TAKASAGO PERFUMERY CO LTD (JP) | 2011-05-11 | — | — | EP | disclosed |
| US-7902207-B2 | Process for production of amines | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2011-03-08 | — | — | US | disclosed |
| US-7473793-B2 | Transition metal (rhodium or ruthenium) complex of a bis(diaryl- or dialicyclylphosphinoaryl) compound and an optionally substituted 1,2-diphenylethylenediamine; hydrogenation catalysts for forming an assymetric alcohol from an assymetric ketone; high optical purity and high yield | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2009-01-06 | — | — | US | disclosed |
| US-20070142639-A1 | Process for production of amines | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2007-06-21 | — | — | US | disclosed |
| US-20060142603-A1 | Transition metal (rhodium or ruthenium) complex of a bis(diaryl- or dialicyclylphosphinoaryl) compound and an optionally substituted 1,2-diphenylethylenediamine; hydrogenation catalysts for forming an assymetric alcohol from an assymetric ketone; high optical purity and high yield | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2006-06-29 | — | — | US | disclosed |
| EP-1661903-A1 | NOVEL TRANSITION METAL COMPLEX AND PROCESS FOR PRODUCING OPTICALLY ACTIVE ALCOHOL WITH THE COMPLEX | Takasago International Corporation (JP) | 2006-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011769-A1 | PROCESS FOR PREPARING 5-(2--1(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE VIA A NOVEL INTERMEDIATE | UGT1A8, UGT1A1, UGT8 | EPHX1 219/4885TP53 4227/4885KDM4E 1691/4885 |
| US-20070142639-A1 | Process for production of amines | SMS, CCNT1, PEAK1 | EPHX1 1098/4885TP53 3844/4885KDM4E 1975/4885 |
| US-20060142603-A1 | Transition metal (rhodium or ruthenium) complex of a bis(diaryl- or dialicyclylphosphinoaryl) compound and an optionally substituted 1,2-diphenylethylenediamine; hydrogenation catalysts for forming an assymetric alcohol from an assymetric ketone; high optical purity and high yield | ADH1A, ADH5, ADH1C | EPHX1 3628/4885TP53 3994/4885KDM4E 586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.